Showing posts with label antibiotics. Show all posts
Showing posts with label antibiotics. Show all posts

Monday, May 23, 2011

Biotech fills Pharma gap

antibiotics


A recent article in Bloomberg Business Week says that only two of the top 6 drugmakers (as determined by market value) are developing antibiotics. As IPs and pharmacists, many of our readers are already well aware of this neglected area of development. The void in the market has created an opportunity for sufficiently innovative competitors, and biotechnology companies are getting into the business as a result.

Big pharma has been getting out of the antibiotics business because the revenue potential for antibiotics is significantly lower than for medications used to treat chronic illness. Antibiotics are used in limited courses for several weeks at a time, as opposed to medicines that are used to treat chronic conditions over long periods. Additionally, as Bloomberg Business Week notes, doctors are advised to limit use of antibiotics because of concerns that overuse can cause resistance. Both these factors have a negative effect on antibiotic sales, removing the motivation for big pharma companies to develop new antibiotics. (It's worth noting that the concern about drug resistance is a well-founded one; drug-resistant bacteria cost the US healthcare system more than $34 billion and 100,000 lives last year, according to the Infection Disease Society of America, as cited by Bloomberg Business Week.)

We’ve previously written about the shortage of new antibiotic development on this blog, particularly as relates to NDM-1, and it’s comforting to know that some companies are trying to fill the general void. Bloomberg mentions Optimer Pharmaceuticals Inc. as an example of a biotech company developing an antibiotic. Optimer’s Dificid, developed to treat Clostridium difficile infections, could potentially be approved by the FDA by the end of this month. If so, it would be the first drug approved to treat C. diff in 25 years.

Other companies mentioned in the article are Trius Therapeutics, The Medicines Co., Paratek Pharmaceuticals Inc., Cubist Pharmaceuticals Inc., and Durata Therapeutics. All are in final testing of antibiotics that would be submitted for FDA approval in the next two to three years. While it’s certainly good to develop new lines of attack for bugs that are resistant to current antibiotics, it definitely does not diminish the need for vigilance when prescribing the currently existing drugs.

Article in Bloomberg Business Week: http://www.businessweek.com/news/2011-05-17/drug-resistant-germs-lure-biotechs-to-create-new-antibiotics.html

Tuesday, June 29, 2010

Monday Readings

I want to share two articles from yesterday's New York Times and Wall Street Journal. The first piece from the NY Times talks about FDA's new policy proposal to limit the use of antibiotics in animal feed. There is an apparently an on-going battle between public health and agriculture over the use of antibiotics in animal feed. The prevalent use of antibiotics such as penicillin and tetracycline in water and feed increases the emergence of resistant bacteria, which many believe to be an important public health issue. FDA's new policy calls for limited use of antibiotics. Whether or not the policy can be passed into law remains to be seen.

The second article from the Wall Street Journal describes quantitative measures implemented by many businesses, including hospitals, to evalute performance of employees. The article uses Long Island Jewish Medical Center as an example. Instead of evaluating nurses on qualitative metrics like "leadership" or "respectfulness," the hospital adopted a computer-based performance system that evaluates nurses against quantifiable goals such as keeping infection rates low and patient-satisfaction scores high. One of the key drivers behind the change is that insurers will begin paying hospitals for care based in part on patient satisfaction, which will be collected by surveys after patients are discharged. So hospitals are aligning performance measures to financial incentive.

http://www.nytimes.com/2010/06/29/health/policy/29fda.html
http://online.wsj.com/article/SB10001424052748703964104575334832074865058.html?mod=WSJ_hpp_sections_careerjournal